BIOMAT Database Logo BIOMAT Database Logo

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns. 2023

David Sánchez Fabra, and Tina Herrero Jordán
F.E.A (Facultativo Especialistas de Área) de Medicina Interna, Servicio de Medicina Interna del Hospital Reina Sofía de Tudela, Tudela, Navarra, Spain.

UI MeSH Term Description Entries

Related Publications

David Sánchez Fabra, and Tina Herrero Jordán
Paxlovid (nirmatrelvir/ritonavir).
January 2022, WMJ : official publication of the State Medical Society of Wisconsin,
David Sánchez Fabra, and Tina Herrero Jordán
[Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination].
June 2022, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia,
David Sánchez Fabra, and Tina Herrero Jordán
Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022.
January 2023, Therapie,
David Sánchez Fabra, and Tina Herrero Jordán
[Nirmatrelvir/ritonavir (Paxlovid®), a treatment for Covid-19].
June 2022, Actualites pharmaceutiques,
David Sánchez Fabra, and Tina Herrero Jordán
Nirmatrelvir Plus Ritonavir: First Approval.
April 2022, Drugs,
David Sánchez Fabra, and Tina Herrero Jordán
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
June 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
David Sánchez Fabra, and Tina Herrero Jordán
Safety and Tolerability of Paxlovid (Nirmatrelvir/Ritonavir) in High-risk Patients.
November 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
David Sánchez Fabra, and Tina Herrero Jordán
Nirmatrelvir plus ritonavir in COVID-19: a profile of its use.
January 2023, Drugs & therapy perspectives : for rational drug selection and use,
David Sánchez Fabra, and Tina Herrero Jordán
Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin.
January 2023, Journal of medical toxicology : official journal of the American College of Medical Toxicology,
David Sánchez Fabra, and Tina Herrero Jordán
Correction to: Nirmatrelvir Plus Ritonavir: First Approval.
June 2022, Drugs,
Copied contents to your clipboard!